Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**5'-O-(N-(Alanyl)sulfamoyl)adenosine** is a synthetic purine nucleoside analog and an experimental small molecule compound. It consists of an adenosine core modified at the 5' position with a sulfamoyl group linked to an alanyl moiety. The compound is not approved for clinical use and has no known marketed indications or completed clinical trials. Its primary research interest lies in its role as a molecular probe or inhibitor in biochemical studies involving aminoacyl-tRNA synthetases and related enzymatic pathways. The mechanism of action is presumed to involve competitive inhibition of enzymes that utilize adenosine derivatives as substrates or cofactors[1][9]. No evidence exists for therapeutic development beyond preclinical/experimental settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5'-O-(N-(Alanyl)sulfamoyl)adenosine.